Vivanza Biosciences Share Price Today | Stock Price & Vivanza Biosciences Share Screener
As of November 18, 2026, the live Vivanza Biosciences share price (BSE: VIVANZA) is ₹1.40, down 1.41% from the previous close, with shares trading between ₹1.31 and ₹1.50 in today's trading session, and a 52-week range of ₹1.36–₹2.40. Track Vivanza Biosciences marketcap in USD to gauge the company's total market size. Use the Vivanza Biosciences stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Vivanza Biosciences opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Key Statistics and Valuation Ratios
Vivanza Biosciences Share Price Chart
Track the current stock price of Vivanza Biosciences with an interactive chart. Analyse VIVANZA share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Vivanza Biosciences stock quote in one place.
The quote of ₹1.40 sits between the 52-week low of ₹1.36 and the 52-week high of ₹2.40, and the latest session moved -1.41% from the previous close.
Vivanza Biosciences Company Profile - Fundamental Screener
Screen Vivanza Biosciences company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for VIVANZA shares across the equity market and its stock price history, plus the wider market trend.
The company is classified under the Healthcare sector and the Pharmaceuticals & Biotechnology industry, and it trades under ISIN INE984E01035.
Company Details
Classification
Identifiers and Leadership
Vivanza Biosciences Balance Sheet Screener
Screen VIVANZA balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.
For 2026, total assets were ₹22, up from ₹17 in 2025.
Latest statistics put total assets at ₹22 and shareholder funds at ₹4, with a leverage ratio of 2.26.
| Item | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
Assets |
||||||||||
| Total Assets | 22 | 17 | 20 | 23 | 16 | 8 | 12 | 11 | 10 | 7 |
| Current Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Fixed Assets | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
Liabilities |
||||||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 1 | 3 | 3 | 1 | 3 | 0 | 0 | 1 | 1 | 0 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Shareholders' Equity |
||||||||||
| Total Equity | 4 | 4 | 5 | 4 | 4 | 3 | 3 | 3 | 4 | 4 |
| Share Capital | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 |
| Reserves & Surplus | 0 | 0 | 1 | 0 | -1 | -1 | -1 | -1 | 0 | -1 |
Vivanza Biosciences Income Statement Screener - Profit & Revenue Analysis
Screen Vivanza Biosciences income statement and profit fundamentals. Analyze VIVANZA quarterly results. Vivanza Biosciences reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.
For 2026-Sept, revenue was ₹11 and net profit was ₹0, equal to earnings per unit of ₹0.03, at an operating margin of 2%.
In that period expenses were ₹11, interest cost ₹0 and tax ₹0. The next period listed, 2026-Jun, shows revenue of ₹10 and net profit of ₹0.
| Item | 2026-Sept | 2026-Jun | 2026-Mar | 2025-Dec | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Dec | 2024-Sept | 2024-Jun | 2024-Mar | 2023-Dec | 2023-Sept | 2023-Jun | 2023-Mar |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue and Expenses | |||||||||||||||
| Revenue | 11 | 10 | 6 | 45 | 55 | 9 | 1 | 2 | 3 | 2 | 4 | 7 | 8 | 9 | 8 |
| Expenses | 11 | 9 | 7 | 45 | 55 | 9 | 1 | 1 | 3 | 2 | 5 | 6 | 7 | 9 | 8 |
Operating Costs and Margins | |||||||||||||||
| EBITDA | 0 | 0 | 0 | 0 | 1 | 0 | -1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Operating Profit % | 2.00% | -1.00% | -4.00% | 0.00% | 1.00% | 2.00% | -200.00% | 8.00% | 4.00% | 15.00% | -3.00% | 4.00% | 4.00% | 6.00% | 0.00% |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Profit and Earnings | |||||||||||||||
| Profit Before Tax | 0 | 0 | 0 | 0 | 1 | 0 | -1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Profit | 0 | 0 | 0 | 0 | 1 | 0 | -1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| EPS | 0.03 | 0.04 | -0.11 | 0.05 | 0.14 | 0.02 | -0.25 | 0.01 | 0.00 | 0.07 | -0.10 | 0.05 | 0.07 | 0.12 | -0.26 |
Vivanza Biosciences Cash Flow Screener - Liquidity Fundamentals
Screen VIVANZA cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.
In 2026-March, operating activities used ₹3.
Over the same period, investing activities provided ₹0 and financing activities provided ₹3.
| Item | 2026-March | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations and Investing | ||||||||||
| Operating Activities | -3 | -3 | 2 | -1 | 3 | -3 | 3 | 1 | 0 | -2 |
| Investing Activities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
Financing and Net Cash | ||||||||||
| Financing Activities | 3 | 3 | -2 | 1 | -3 | 3 | -3 | -1 | -1 | 0 |
| Net Cash Flow | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -1 | 0 |
Vivanza Biosciences Shareholding Pattern Screener
See Vivanza Biosciences shareholding pattern with promoter, FII, and DII holdings. Check Vivanza Biosciences promoter holding and ownership changes for VIVANZA on TickJournal, and see how institutional stock price moves affect the market.
In 2026-Mar, promoters held 20.02%, foreign institutions 0.00%, domestic institutions 0.00% and the public 73.34%, spread across 19,461 shareholders.
The shareholder count was 19,461 in 2026-Mar, compared with 19,254 in 2026-Jun.
| Item | 2026-Mar | 2026-Jun | 2026-Sept | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar |
|---|---|---|---|---|---|---|---|---|
Promoter Holding | ||||||||
| Promoter Holding | 20.02% | 20.02% | 20.02% | 20.02% | 20.02% | 20.02% | 20.02% | 43.24% |
Institutional Investors | ||||||||
| FII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| DII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Government, Public and Others | ||||||||
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 73.34% | 73.49% | 73.90% | 73.69% | 73.36% | 73.34% | 73.42% | 13.82% |
| Other Holding | 6.64% | 6.49% | 6.07% | 6.29% | 6.62% | 6.64% | 6.56% | 42.94% |
| Shareholder Count | 19,461 | 19,254 | 19,366 | 20,833 | 20,458 | 20,170 | 19,822 | 6,992 |
Dividend Yield Screener - Share Price & Share Analysis
Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Vivanza Biosciences. Vivanza Biosciences dividend yield can be compared with peers and other stocks in the market.
Vivanza Biosciences Stock Index Membership - Nifty & Sensex
See which indices include Vivanza Biosciences stock. Check VIVANZA index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.
Complete Index List
Vivanza Biosciences Market Events Screener - Corporate Actions
Get Vivanza Biosciences corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Vivanza Biosciences stock events that may affect VIVANZA share price, along with derivatives, futures and options activity and sector gainers.
14 corporate actions are listed, the most recent entry being Quarterly Result Announcement dated November 6, 2026, with a record date of November 6, 2026.
It is followed by Annual General Meeting dated September 11, 2026 and Quarterly Result Announcement dated August 7, 2026.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-11-06 | 2026-11-06 | Quarterly Result Announcement | NA | -8.33% |
| 2026-09-11 | 2026-09-11 | Annual General Meeting | NA | 6.21% |
| 2026-08-07 | 2026-08-07 | Quarterly Result Announcement | NA | 4.42% |
| 2026-05-07 | 2026-05-07 | Quarterly Result Announcement | NA | -2.44% |
| 2026-02-12 | 2026-02-12 | Quarterly Result Announcement | NA | 2.44% |
| 2025-11-11 | 2025-11-11 | Quarterly Result Announcement | NA | 0.51% |
| 2025-09-25 | 2025-09-25 | Annual General Meeting | NA | -0.48% |
| 2025-08-13 | 2025-08-13 | Quarterly Result Announcement | NA | 2.45% |
| 2025-05-12 | 2025-05-12 | Quarterly Result Announcement | NA | -4.59% |
| 2025-01-31 | 2025-01-31 | Quarterly Result Announcement | NA | -2.93% |
| 2024-10-17 | 2024-10-17 | Quarterly Result Announcement | NA | -6.39% |
| 2024-08-01 | 2024-08-01 | Annual General Meeting | NA | -4.19% |
| 2023-03-24 | 2023-03-24 | Split | 1:10 | 34.08% |
| 2022-07-21 | 2022-07-21 | Annual General Meeting | NA | 3.17% |
Vivanza Biosciences Competitors Screener - Peer Stocks Comparison
Screen VIVANZA competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.
The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 451,531 | 41.10 | 61,674 | 12.69% | 11,565 | 63.60 |
| Divis Laboratories | 297,351 | 90.70 | 11,067 | 13.95% | 2,568 | 78.53 |
| Torrent Pharmaceuticals | 179,283 | 84.50 | 13,886 | 20.34% | 2,138 | 47.27 |
| Laurus Labs | 123,391 | 98.10 | 6,868 | 22.01% | 890 | 69.60 |
| Zydus Life Science | 119,511 | 27.60 | 27,658 | 17.64% | 5,026 | 52.34 |
| Dr Reddys Laboratories | 115,804 | 41.70 | 35,059 | 3.90% | 4,158 | 70.24 |
| Cipla | 112,486 | 39.40 | 29,045 | 2.24% | 3,870 | 54.92 |
| Mankind Pharma | 109,374 | 48.40 | 14,636 | 14.85% | 1,938 | 65.43 |
| Aurobindo Pharma | 104,529 | 26.40 | 34,145 | 5.56% | 3,503 | 66.06 |
| Lupin | 90,932 | 17.30 | 29,039 | 26.75% | 5,356 | 44.92 |
Vivanza Biosciences Company Announcements - News & Reports Screener
Screen VIVANZA latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.
20 recent announcements are listed, the latest dated November 11, 2026.
The next most recent announcements are dated November 10, 2026 and November 3, 2026.
| Date | Update | Actions |
|---|---|---|
| 2026-11-11 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-11-10 | Board Meeting Outcome for Outcome Of Board Of Directors Meeting Of Vivanza Biosciences Limited Held On 06.11.2026 | - |
| 2026-11-03 | Board Meeting Intimation for Postponement And Rescheduling Of Board Meeting Pursuant To Regulation 29 & 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 | - |
| 2026-10-29 | Non-Applicability Of Regulation 23(9) Of SEBI (LODR) Regulations 2015 Regarding Submission Of Disclosures Of Related Party Transactions For The Half Year Ended On September 30 2026 | - |
| 2026-10-28 | Board Meeting Intimation for Consider And Approve 1. Unaudited Standalone And Consolidated Financial Results Along With Limited Review Report Of The Company For The Quarter And Half Year Ended September 30 2026 | - |
| 2026-10-08 | Non Applicability Of Statement Of Deviation Or Variation Under Regulation 32 Of SEBI LODR Regulations 2015 | - |
| 2026-10-02 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2026-09-28 | Closure of Trading Window | - |
| 2026-09-12 | Shareholder Meeting / Postal Ballot-Scrutinizers Report | - |
| 2026-09-12 | Shareholder Meeting / Postal Ballot-Outcome of AGM | - |
| 2026-09-11 | Shareholder Meeting / Postal Ballot-Outcome of AGM | - |
| 2026-08-20 | Announcement Under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-08-19 | Reg. 34 (1) Annual Report. | - |
| 2026-08-19 | Notice Of The 44Th Annual General Meeting (AGM) And Annual Report Of The Company For The Financial Year 2025-26 | - |
| 2026-08-17 | Board Meeting Outcome for Outcome Of Board Meeting Held On 17.08.2026 | - |
| 2026-08-12 | Board Meeting Intimation for Intimation Of Board Meeting Under Regulation 29(1)(A) And Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 | - |
| 2026-08-08 | Non Applicability Of Statement Of Deviation Or Variation Under Regulation 32 Of SEBI LODR Regulations 2015 | - |
| 2026-08-08 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-08-07 | Outcome Of Board Of Directors Meeting Of Vivanza Biosciences Limited (The Company) | - |
| 2026-08-07 | Outcome Of Board Of Directors Meeting Of Vivanza Biosciences Limited (The Company) | - |
Frequently Asked Questions
How is the company valued right now?
The current quote is ₹1.40, within a 52-week range of ₹1.36 to ₹2.40. The P/E ratio is 142.00 and the P/B ratio is 1.22, with earnings per unit of ₹0.10. Market capitalisation stands at ₹5.70 Cr. The company operates in the Healthcare sector, in the Pharmaceuticals & Biotechnology industry, so compare these ratios with its sector peers in the table above.
About This Data
Quotes are sourced from the BSE. Key statistics were last updated on November 19, 2026. This page covers 10 balance sheet periods, 15 income statement periods, 10 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.